Hantschel, Oliver2015-03-092015-03-092015-03-09201510.1182/blood-2014-12-617548https://infoscience.epfl.ch/handle/20.500.14299/11222325721043In this issue of Blood, Appelmann et al provide evidence for prolonged survival and prevention of resistance in a mouse model of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) by combined targeting of the BCR-ABL kinase and Janus kinase 2 (JAK2) with dasatinib and ruxolitinib, respectively. © 2015 by The American Society of Hematology.text::journal::journal article::research article